Table 1 Baseline characteristics of the study population.
| Ā | Ā | Ā | Total (nā=ā200) | Control arm (nā=ā100) | Ki-67 response-guided arm (nā=ā100) | P value** | |||
|---|---|---|---|---|---|---|---|---|---|
| Ā | Ā | Ā | n | % | n | % | n | % | Ā |
Age, years | Median (range) | 57.3 (25ā75) | 56.7 (25ā72) | 58.3 (31ā75) | 0.115 | ||||
Pretreatment Ki-67 index* | Mean (SD) | 51.8 (17.8) | 49.9 (16.6) | 53.6 (18.8) | 0.150 | ||||
Tumour size by palpation, (cm) | Mean (SD) | 4.2 (2.8) | 3.8 (1.6) | 4.5 (3.5) | 0.0752 | ||||
Clinical tumour stageā | Ā | cT1 | 16 | 8.0 | 11 | 11.0 | 5 | 5.0 | 0.403 |
| Ā | Ā | cT2 | 145 | 72.5 | 70 | 70.0 | 75 | 75.0 | Ā |
| Ā | Ā | cT3 | 26 | 13.0 | 12 | 12.0 | 14 | 14.0 | Ā |
| Ā | Ā | cT4 | 10 | 5.0 | 6 | 6.0 | 4 | 4.0 | Ā |
| Ā | Ā | NA | 3 | 1.5 | 1 | 1.0 | 2 | 2.0 | Ā |
Clinical nodal statusā | Ā | cN0 | 73 | 36.5 | 32 | 32.0 | 41 | 41.0 | 0.124 |
| Ā | Ā | cN1 | 99 | 49.5 | 55 | 55.0 | 44 | 44.0 | Ā |
| Ā | Ā | cN2 | 16 | 8.0 | 5 | 5.0 | 11 | 11.0 | Ā |
| Ā | Ā | cN3 | 12 | 6.0 | 8 | 8.0 | 4 | 4.0 | Ā |
Clinical stageā | Ā | I | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0.481 |
| Ā | Ā | IIA | 80 | 40.0 | 37 | 37.0 | 43 | 43.0 | Ā |
| Ā | Ā | IIB | 68 | 34.0 | 37 | 37.0 | 31 | 31.0 | Ā |
| Ā | Ā | IIIA | 32 | 16.0 | 14 | 14.0 | 18 | 18.0 | Ā |
| Ā | Ā | IIIB | 7 | 3.5 | 3 | 3.0 | 4 | 4.0 | Ā |
| Ā | Ā | IIIC | 13 | 6.5 | 9 | 9.0 | 4 | 4.0 | Ā |
Histology | Ā | Ductal invasive | 185 | 92.5 | 92 | 92.0 | 93 | 93.0 | 0.845 |
| Ā | Ā | Lobular invasive | 7 | 3.5 | 3 | 3.0 | 4 | 4.0 | Ā |
| Ā | Ā | Other | 8 | 4.0 | 5 | 5.0 | 3 | 3.0 | Ā |
Hormone statusā ,ā” | Receptor | ERā/PgRā | 91 | 45.5 | 45 | 45.0 | 46 | 46.0 | 1.000 |
| Ā | Ā | ERā/PgR+ | 5 | 2.5 | 3 | 3.0 | 2 | 2.0 | Ā |
| Ā | Ā | ER+/PgRā | 37 | 18.5 | 18 | 18.0 | 19 | 19.0 | Ā |
| Ā | Ā | ER+/PgR+ | 67 | 33.5 | 34 | 34.0 | 33 | 33.0 | Ā |
